Tom Woiwode

Tom Woiwode is a managing director at Versant Ventures and has been working there since 2002. He has led multiple investments, including in Crispr Therapeutics, Passage Bio, Audentes Therapeutics, Annapurna Therapeutics, Gritstone Bio, Crinetics Pharmaceuticals, Jecure Therapeutics, Therachon, Anokion, Vividion Therapeutics, Tempest Therapeutics, Aligos Therapeutics and CODA Biotherapeutics. Before joining Versant, he served as a medicinal chemist at XenoPort. He earned his Ph.D. in chemistry from Stanford University and a B.S. in chemistry from University of California, Berkeley.